GlassScriptPhysician profile
Casey M Jensen
NPI 1326560087
$3,349.55
in general payments reported to CMS, 2019-2025
29 companies · $830 in 2025
The $830 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.21 · 2023: $967 · 2024: $1,490 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,287.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $533.36 | 2022-2025 | |
| Novo Nordisk INC | $347.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $327.68 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $291.07 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $268.31 | 2024-2025 | Fanapt, Hetlioz |
| Astrazeneca Pharmaceuticals LP | $198.96 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $177.92 | 2023-2025 | |
| Amgen INC. | $177.31 | 2023-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $139.34 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $97.90 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $78.91 | 2023-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $72.97 | 2023-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.23 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $58.74 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $56.91 | 2023-2025 | Lybalvi, Vivitrol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $56.27 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $53.09 | 2023-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $52.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $52.09 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $43.52 | 2023-2024 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $36.07 | 2023-2024 | Quviviq |
| Baxter Healthcare | $30.84 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $28.41 | 2025 | Minimed 780g |
| Lundbeck LLC | $19.33 | 2025 | Rexulti |
| Boston Scientific Corporation | $18.96 | 2024 | |
| Dynavax Technologies Corporation | $18.45 | 2025 | Heplisav-B |
| Abbott Laboratories | $16.13 | 2023 | Freestyle Libre |
| Currax Pharmaceuticals LLC | $14.47 | 2025 | Contrave |
| Sanofi-Aventis U.S. LLC | $13.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casey Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.